Diabetic angiopathy and angiogenic defects-Reference-Cited by-同舟云学术

Diabetic angiopathy and angiogenic defects

Published:2012-08-01 Issue:1 Volume:5 Page:
ISSN:1755-1536
Container-title:Fibrogenesis & Tissue Repair
language:en
Short-container-title:Fibrogenesis Tissue Repair

Author:

Xu Ling,Kanasaki Keizo,Kitada Munehiro,Koya Daisuke

Abstract

Abstract Diabetes is one of the most serious health problems in the world. A major complication of diabetes is blood vessel disease, termed angiopathy, which is characterized by abnormal angiogenesis. In this review, we focus on angiogenesis abnormalities in diabetic complications and discuss its benefits and drawbacks as a therapeutic target for diabetic vascular complications. Additionally, we discuss glucose metabolism defects that are associated with abnormal angiogenesis in atypical diabetic complications such as cancer.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Dermatology,Hepatology,Rheumatology,Medicine (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1186/1755-1536-5-13.pdf

Reference132 articles.

1. Kopelman P: Health risks associated with overweight and obesity. Obes Rev. 2007, Suppl 1: 13-17.

2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329: 977-986.

3. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865.

4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995, 28: 103-117. 10.1016/0168-8227(95)01064-K.

5. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, for the ACCORD trial group: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010, 376: 419-430. 10.1016/S0140-6736(10)60576-4.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex-Specific Cytokine, Chemokine, and Growth Factor Signatures in T1D Patients and Progressors;2024-09-07

2. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

3. The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives;Cancers;2024-03-05

4. Physiology and Pathophysiology of Wound Healing in Diabetes;Contemporary Diabetes;2024

5. Single-cell transcriptomics identifies adipose tissue CD271+ progenitors for enhanced angiogenesis in limb ischemia;Cell Reports Medicine;2023-12